Global Radiopharmaceuticals in Nuclear Medicine
Market 2022 by Manufacturers, Regions, Type and
Application, Forecast to 2028
Bharat Book Bureau Provides the Trending Industry Research Report on“Global
Radiopharmaceuticals in Nuclear Medicine Market 2022 by Manufacturers, Regions, Type
and Application, Forecast to 2028”under Life Sciences Market Research Report. The report
offers a collection of superior Market research, Market analysis, competitive intelligence and
Market reports.
Executive Summary
The Radiopharmaceuticals in Nuclear Medicine Market report provides a detailed analysis of
global market size, regional and country-level market size, segmentation market growth, market
share, competitive Landscape, sales analysis, impact of domestic and global market players,
value chain optimization, trade regulations, recent developments, opportunities analysis, strategic
market growth analysis, product launches, area marketplace expanding, and technological
innovations.
According to our latest study, due to COVID-19 pandemic, the global Radiopharmaceuticals in
Nuclear Medicine market size is estimated to be worth US$ 4943.7 million in 2021 and is
forecast to a readjusted size of USD 6857.2 million by 2028 with a CAGR of 4.8% during
review period. Diagnostic Application accounting for % of the Radiopharmaceuticals in Nuclear
Medicine global market in 2021, is projected to value USD million by 2028, growing at a %
CAGR in next six years. While Diagnostic Radiopharmaceuticals segment is altered to a %
CAGR between 2022 and 2028.
Global key manufacturers of Radiopharmaceuticals in Nuclear Medicine include Bracco Imaging
S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, and
Eczacibasi-Monrol, etc. In terms of revenue, the global top four players hold a share over % in
2021.
Market segmentation
Radiopharmaceuticals in Nuclear Medicine market is split by Type and by Application. For the
period 2017-2028, the growth among segments provide accurate calculatio